Actively Recruiting
Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
Led by Central Hospital, Nancy, France · Updated on 2024-08-27
100
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of mortality. SSc-ILD is variable: from limited forms (with asymptomatic patients) to extensive lesions. Disease course in SSc-ILD is also highly variable: patients can experience stable disease, slow or fast progression. Investigators performed unsupervised clustering analysis to classify SSc-ILD according to elementary radiological lesions on HRCT scan.
CONDITIONS
Official Title
Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with systemic sclerosis according to 2013 ACR/EULAR criteria
- Patients with interstitial lung disease on HRCT chest
You will not qualify if you...
- Patients with an alternative diagnosis of SSc-associated ILD such as silicosis, sarcoidosis, lung cancer, or other significant lung abnormalities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Central Hospital
Nancy, France
Actively Recruiting
Research Team
P
Paul DECKER, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here